Total Payments
$5,551
2024 Payments
$434.94
Companies
13
Transactions
32
Medicare Patients
7,459
Medicare Billing
$5.4M
Payment Breakdown by Category
Research$3,184 (57.4%)
Consulting$2,100 (37.8%)
Food & Beverage$244.22 (4.4%)
Education$22.79 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,184 | 16 | 57.4% |
| Consulting Fee | $2,100 | 1 | 37.8% |
| Food and Beverage | $244.22 | 13 | 4.4% |
| Education | $22.79 | 2 | 0.4% |
Payments by Type
Research
$3,184
16 transactions
General
$2,367
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $5,284 | 17 | $0 (2024) |
| PFIZER INC. | $61.39 | 3 | $0 (2024) |
| ABBVIE INC. | $31.81 | 1 | $0 (2024) |
| Daiichi Sankyo Inc. | $24.97 | 1 | $0 (2023) |
| Merck Sharp & Dohme LLC | $23.76 | 2 | $0 (2022) |
| Astellas Pharma US Inc | $22.47 | 1 | $0 (2023) |
| KARL STORZ Endoscopy-America | $17.95 | 1 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $16.72 | 1 | $0 (2024) |
| ARRAY BIOPHARMA INC | $15.26 | 1 | $0 (2024) |
| TerSera Therapeutics LLC | $14.79 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $434.94 | 11 | Regeneron Pharmaceuticals, Inc. ($327.46) |
| 2023 | $839.38 | 12 | Regeneron Pharmaceuticals, Inc. ($730.32) |
| 2022 | $2,154 | 6 | Regeneron Pharmaceuticals, Inc. ($2,126) |
| 2021 | $22.79 | 2 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $2,100 | 1 | Regeneron Pharmaceuticals, Inc. ($2,100) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $95.37 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/16/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $24.24 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $102.56 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/30/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $24.24 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $32.57 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/09/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $31.81 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $48.48 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/14/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: ONCOLOGY | ||||||
| 01/25/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Genetic Disease | ||||||
| 01/18/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Oncology | ||||||
| 11/01/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $138.30 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/21/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $318.70 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/28/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $28.11 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/07/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $28.11 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/17/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: ONCOLOGY | ||||||
| 07/27/2023 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $12.98 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $136.29 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 04/15/2023 | KARL STORZ Endoscopy-America | TELE PACK (Device) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: VIDEOIMAGING | ||||||
| 03/29/2023 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $80.81 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/09/2023 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: Oncology | ||||||
| 11/02/2022 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Oncology | ||||||
| 09/12/2022 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $872.96 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $3,184 | 16 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 1,836 | 100,391 | $5.5M | $1.9M |
| 2022 | 45 | 1,771 | 128,260 | $4.3M | $1.4M |
| 2021 | 44 | 1,792 | 120,675 | $3.8M | $1.3M |
| 2020 | 53 | 2,060 | 100,523 | $2.5M | $840,877 |
Total Patients
7,459
Total Services
449,849
Medicare Billing
$5.4M
Procedure Codes
186
All Medicare Procedures & Services
186 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 21 | 21,600 | $2.7M | $932,716 | 34.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 19 | 31,840 | $1.9M | $755,255 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 267 | 707 | $194,425 | $64,106 | 33.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 112 | 395 | $118,200 | $37,671 | 31.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 1,440 | $50,400 | $26,558 | 52.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 106 | 154 | $53,900 | $20,366 | 37.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 11 | 10,500 | $52,500 | $9,193 | 17.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $23,100 | $7,149 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 110 | 118 | $26,550 | $6,334 | 23.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 41 | 43 | $18,275 | $5,536 | 30.3% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 14 | 40 | $14,000 | $4,699 | 33.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 79 | 396 | $21,780 | $4,502 | 20.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 74 | $12,195 | $4,422 | 36.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 60 | 201 | $14,271 | $4,260 | 29.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 35 | 88 | $13,200 | $4,176 | 31.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 50 | 78 | $11,700 | $3,635 | 31.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 39 | $8,775 | $3,506 | 40.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 38 | 184 | $8,096 | $2,756 | 34.0% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 51 | 18,150 | $90,750 | $2,264 | 2.5% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 51 | 213 | $7,029 | $1,960 | 27.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,775 | $1,750 | 30.3% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 22 | 57 | $7,125 | $1,547 | 21.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 68 | $4,420 | $1,425 | 32.2% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 26 | 55 | $6,050 | $1,337 | 22.1% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 46 | 77 | $4,620 | $1,221 | 26.4% |
About Dr. Yungpo Su, MD
Dr. Yungpo Su, MD is a Hematology & Oncology healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457322166.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yungpo Su, MD has received a total of $5,551 in payments from pharmaceutical and medical device companies, with $434.94 received in 2024. These payments were reported across 32 transactions from 13 companies. The most common payment nature is "" ($3,184).
As a Medicare-enrolled provider, Su has provided services to 7,459 Medicare beneficiaries, totaling 449,849 services with total Medicare billing of $5.4M. Data is available for 4 years (2020–2023), covering 186 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Omaha, NE
- Active Since 01/30/2006
- Last Updated 07/31/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1457322166
Products in Payments
- LIBTAYO (Biological) $5,284
- IBRANCE (Drug) $46.27
- IMBRUVICA (Drug) $31.81
- Enhertu (Drug) $24.97
- KEYTRUDA (Biological) $23.76
- Xospata (Drug) $22.47
- TELE PACK (Device) $17.95
- GIVLAARI (Drug) $16.72
- BRAFTOVI (Drug) $15.26
- PADCEV (Biological) $15.12
- Xermelo (Drug) $14.79
- JEVTANA (Drug) $12.99
- OPDUALAG (Drug) $12.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Omaha
James Armitage, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Margaret Block, M.d, M.D
Hematology & Oncology — Payments: $444,214
Hematology & Oncology $444,214
Julie Vose, Md, MD
Hematology & Oncology — Payments: $194,187
Hematology & Oncology $194,187
Peter Silberstein, M.d, M.D
Hematology & Oncology — Payments: $143,878
Hematology & Oncology $143,878
Apar Kishor Ganti, Md, MD
Hematology & Oncology — Payments: $135,871
Hematology & Oncology $135,871
Dr. Krishna Gundabolu, M.d, M.D
Hematology & Oncology — Payments: $75,519
Hematology & Oncology $75,519